...
首页> 外文期刊>Urology Annals >Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
【24h】

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin

机译:EORTC风险组计算器和分子标志物联合使用对膀胱内BacilleCalmette-Guérin治疗的非肌肉浸润性膀胱癌患者的长期预后价值

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background and Objectives: To evaluate the long-term prognostic value of the combination of the EORTC risk calculator and proapoptotic, antiapoptotic, proliferation, and invasiveness molecular markers in predicting the outcome of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) treated with intravesical Bacille Calmette-Guérin (BCG) therapy. Materials and Methods: This study included 42 patients accrued prospectively presenting with intermediate- to high-risk NMIBC (high-grade T1 tumors or multiple rapidly recurrent tumors refractory to intravesical chemotherapy) treated with transurethral resection (TUR) and BCG. TUR samples were analyzed for the molecular markers p53, p21 waf1/cip, Bcl-2, CyclinD1, and metallothionein 9 (MMP9) using immunohistochemistry. Frequency of positivity, measured as a percentage, was assessed alone or in combination with EORTC risk calculator, for interaction with outcome in terms of recurrence and progression using univariate analysis and Kaplan-Meier survival curves. Results: Median follow-up was 88 months (mean, 99; range, 14-212 months). The overall recurrence rate was 61.9% and progression rate was 21.4%. In univariate analysis, CyclinD1 and EORTC risk groups were significantly associated with recurrence (P value 0.03 and 0.02, respectively), although none of the markers showed a correlation to progression. In combining EORTC risk groups to markers expression status, high-risk group associated with positive MMP9, Bcl-2, CyclinD1, or p21 was significantly correlated to tumor recurrence (log rank P values P values 0.01 and 0.04, respectively). Conclusion: Molecular markers have a long-term prognostic value when combined with EORTC scoring system and they may be used to improve the predictive accuracy of currently existing scoring system. Larger series are needed to confirm these findings.
机译:背景与目的:评价EORTC风险计算器与促凋亡,抗凋亡,增殖和侵袭性分子标志物联合使用对预测中,高危非肌肉侵袭性膀胱癌预后的长期预后价值( NMIBC)经膀胱内BacilleCalmette-Guérin(BCG)治疗。资料和方法:本研究纳入了42例经尿道切除术(TUR)和BCG治疗的前瞻性表现为中至高危NMIBC(高级别T1肿瘤或难于膀胱内化疗的多发快速复发肿瘤)的患者。使用免疫组织化学分析TUR样品中的分子标记p53,p21 waf1 / cip,Bcl-2,CyclinD1和金属硫蛋白9(MMP9)。使用单变量分析和Kaplan-Meier生存曲线,可以单独或与EORTC风险计算器结合评估阳性率,以与复发和进展相关的结果进行交互,以百分比表示。结果:中位随访时间为88个月(平均99个月;范围14-212个月)。总体复发率为61.9%,进展率为21.4%。在单变量分析中,CyclinD1和EORTC风险组与复发显着相关(分别为P值0.03和0.02),尽管这些标志物均未显示与进展相关。通过将EORTC风险组与标志物表达状态结合起来,与阳性MMP9,Bcl-2,CyclinD1或p21相关的高风险组与肿瘤复发显着相关(对数秩P值P值分别为0.01和0.04)。结论:分子标记物与EORTC评分系统结合具有长期的预后价值,可用于提高现有评分系统的预测准确性。需要更大的序列来确认这些发现。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号